Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 182

1.

Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation.

Ohka F, Ito M, Ranjit M, Senga T, Motomura A, Motomura K, Saito K, Kato K, Kato Y, Wakabayashi T, Soga T, Natsume A.

Tumour Biol. 2014 Jun;35(6):5911-20. doi: 10.1007/s13277-014-1784-5. Epub 2014 Mar 5.

PMID:
24590270
2.

Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death.

Mohrenz IV, Antonietti P, Pusch S, Capper D, Balss J, Voigt S, Weissert S, Mukrowsky A, Frank J, Senft C, Seifert V, von Deimling A, Kögel D.

Apoptosis. 2013 Nov;18(11):1416-25. doi: 10.1007/s10495-013-0877-8.

PMID:
23801081
3.

Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1.

Seltzer MJ, Bennett BD, Joshi AD, Gao P, Thomas AG, Ferraris DV, Tsukamoto T, Rojas CJ, Slusher BS, Rabinowitz JD, Dang CV, Riggins GJ.

Cancer Res. 2010 Nov 15;70(22):8981-7. doi: 10.1158/0008-5472.CAN-10-1666. Epub 2010 Nov 2.

4.

D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma.

Pusch S, Schweizer L, Beck AC, Lehmler JM, Weissert S, Balss J, Miller AK, von Deimling A.

Acta Neuropathol Commun. 2014 Feb 14;2:19. doi: 10.1186/2051-5960-2-19.

5.

Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.

Kato Y.

Brain Tumor Pathol. 2015 Jan;32(1):3-11. doi: 10.1007/s10014-014-0202-4. Epub 2014 Oct 17. Review.

PMID:
25324168
6.

R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling.

Cui D, Ren J, Shi J, Feng L, Wang K, Zeng T, Jin Y, Gao L.

Int J Biochem Cell Biol. 2016 Apr;73:72-81. doi: 10.1016/j.biocel.2016.02.007. Epub 2016 Feb 6.

PMID:
26860959
7.

Isocitrate dehydrogenase mutations in gliomas.

Waitkus MS, Diplas BH, Yan H.

Neuro Oncol. 2016 Jan;18(1):16-26. doi: 10.1093/neuonc/nov136. Epub 2015 Jul 16. Review.

8.

Metabolism of glioma and IDH1/IDH2 mutations.

Rossetto M, Ciccarino P, Boisselier B, Labussiere M, Sanson M.

Rev Neurol (Paris). 2011 Oct;167(10):699-703. doi: 10.1016/j.neurol.2011.08.002. Epub 2011 Aug 31. Review.

PMID:
21885076
9.

Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.

Li S, Chou AP, Chen W, Chen R, Deng Y, Phillips HS, Selfridge J, Zurayk M, Lou JJ, Everson RG, Wu KC, Faull KF, Cloughesy T, Liau LM, Lai A.

Neuro Oncol. 2013 Jan;15(1):57-68. doi: 10.1093/neuonc/nos261. Epub 2012 Oct 31.

10.
11.

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.

Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, Sasaki M, Jin S, Schenkein DP, Su SM, Dang L, Fantin VR, Mak TW.

J Exp Med. 2010 Feb 15;207(2):339-44. doi: 10.1084/jem.20092506. Epub 2010 Feb 8.

12.

Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation.

Lazovic J, Soto H, Piccioni D, Lou JR, Li S, Mirsadraei L, Yong W, Prins R, Liau LM, Ellingson BM, Cloughesy TF, Lai A, Pope WB.

Neuro Oncol. 2012 Dec;14(12):1465-72. doi: 10.1093/neuonc/nos258. Epub 2012 Oct 22.

13.

Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.

Pope WB, Prins RM, Albert Thomas M, Nagarajan R, Yen KE, Bittinger MA, Salamon N, Chou AP, Yong WH, Soto H, Wilson N, Driggers E, Jang HG, Su SM, Schenkein DP, Lai A, Cloughesy TF, Kornblum HI, Wu H, Fantin VR, Liau LM.

J Neurooncol. 2012 Mar;107(1):197-205. doi: 10.1007/s11060-011-0737-8. Epub 2011 Oct 21.

14.

A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas.

Fujii Y, Ogasawara S, Oki H, Liu X, Kaneko MK, Takano S, Kato Y.

Biochem Biophys Res Commun. 2015 Oct 30;466(4):733-9. doi: 10.1016/j.bbrc.2015.09.070. Epub 2015 Sep 14.

PMID:
26381180
15.

Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.

Agarwal S, Sharma MC, Jha P, Pathak P, Suri V, Sarkar C, Chosdol K, Suri A, Kale SS, Mahapatra AK, Jha P.

Neuro Oncol. 2013 Jun;15(6):718-26. doi: 10.1093/neuonc/not015. Epub 2013 Mar 13.

16.

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.

Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su SM.

Nature. 2009 Dec 10;462(7274):739-44. doi: 10.1038/nature08617.

17.

Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and α-KG.

Navis AC, Niclou SP, Fack F, Stieber D, van Lith S, Verrijp K, Wright A, Stauber J, Tops B, Otte-Holler I, Wevers RA, van Rooij A, Pusch S, von Deimling A, Tigchelaar W, van Noorden CJ, Wesseling P, Leenders WP.

Acta Neuropathol Commun. 2013 May 29;1:18. doi: 10.1186/2051-5960-1-18.

18.

Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas.

Jin G, Reitman ZJ, Duncan CG, Spasojevic I, Gooden DM, Rasheed BA, Yang R, Lopez GY, He Y, McLendon RE, Bigner DD, Yan H.

Cancer Res. 2013 Jan 15;73(2):496-501. doi: 10.1158/0008-5472.CAN-12-2852. Epub 2012 Nov 30.

19.

Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.

Raghunathan A, Olar A, Vogel H, Parker JR, Coventry SC, Debski R, Albarracin CT, Aldape KD, Cahill DP 3rd, Powell SZ, Fuller GN.

Ann Diagn Pathol. 2012 Aug;16(4):255-9. doi: 10.1016/j.anndiagpath.2011.11.003. Epub 2012 Mar 23.

PMID:
22445362
20.

Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation.

Shi J, Sun B, Shi W, Zuo H, Cui D, Ni L, Chen J.

Tumour Biol. 2015 Feb;36(2):655-62. doi: 10.1007/s13277-014-2644-z. Epub 2014 Oct 5.

PMID:
25283382

Supplemental Content

Support Center